Solomon Islands

Medicines policy and pharmaceutical services in Solomon Islands are overseen by the Ministry of Health and Medical Services (MHMS), including the National Pharmacy Services Division. The Government’s official National Medicines Policy consultation notice explains that the policy is intended to support access to quality, safe and effective medicines, while also acknowledging that the country was still developing a basic regulatory structure for medicine quality, safety and efficacy. Suppliers and product sponsors should therefore maintain appropriate post-market safety surveillance, preserve records, communicate significant adverse reactions or emerging safety issues to MHMS and comply with any safety conditions attached to procurement, importation or product supply. At present, accessible official material does not publish a dedicated national GVP guideline or universal MAH requirements for a local QPPV or PV contact, a PSMF, fixed post-marketing ICSR timelines, scheduled PSUR/PBRER submissions, a national RMP format or a routine pharmacovigilance-inspection cycle. These points should be confirmed directly with MHMS and recorded in product- or supply-specific agreements rather than being inferred from Australian, EU or other foreign rules. BAUPHARMA supporting resources (operational context only, not national regulatory evidence): Effective Signal Management in Pharmacovigilance.